Q-omics provides the consensus-scored CHN2 profile across patient tissues and cancer cell-line models. CHN2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CHN2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CHN2 RNA expression shows 19,107 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where CHN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHN2 survival associations across molecular data types. CHN2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHN2 RNA expression–survival associations across cancer types. High CHN2 expression shows unfavorable associations in UVM, LGG and HNSC, but favorable associations in MESO, SCLC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CHN2 RNA expression.
This table summarizes CHN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CHN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHN2 shows lower tumor expression in KIRC, KICH, KIRP, LUSC, UCEC and LUAD. The KIRC box plot shows higher CHN2 RNA expression in normal versus tumor tissue (log2 FC = −1.145, t-test p < 0.001).
This table shows molecular features associated with CHN2 in patient tissues and cancer cell lines. In patient samples, CHN2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
